Drug Database
HO

Hoe-285 (Hoe 285 / Brainorm / Albex 285)

✓ Approved

Sanofi S.A · Small Molecule · Small Molecule

What is Hoe-285?

Hoe-285 is a small molecule developed by Sanofi S.A. It is approved for therapeutic indications via injectable (others) or intravenous (iv) or oral (po).

Drug Profile

Brand NamesHoe 285, Brainorm, Albex 285
CompanySanofi S.A
Drug ClassSmall Molecule
RouteInjectable (Others), Intravenous (IV), Oral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Sanofi S.A

Therapeutic Indications

Hoe-285 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Nervous system disordersDelayed ischaemic neurological deficit✓ Approved

Related Research Articles

PubMedBMC gastroenterology2026-11-12

Association of D-dimer/Lymphocyte ratio with severity in acute pancreatitis: a cross-sectional study.

He Yiqi Y, Dai Shenglan S

The D-dimer/lymphocyte ratio (DLR) reflects coagulation activation and immune status, but its association with the severity of acute pancreatitis (AP) remains unclear. This study aimed to investigate the relationship between DLR and AP severity. This cross-sectional study included 285 adult patients with AP admitted to the Department of Gastroenterology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, China, between February 2024 and April 2025. Disease severity was classified according to the computed tomography severity index as mild acute pancreatitis (MAP) or moderately severe/severe acute pancreatitis (MSAP/SAP). DLR was calculated as D-dimer divided by lymphocyte count and was log-transformed as LogDLR. Logistic regression and restricted cubic spline (RCS) analyses were used to assess the association between LogDLR and MSAP/SAP. Receiver operating characteristic (ROC) analysis compared the discriminatory performance of LogDLR, NLR, PLR, and CLR; Optimal cut-off values were determined using the maximum Youden index. Among the 285 patients, 202 were classified as MAP and 83 as MSAP/SAP. As LogDLR increased, age, C-reactive protein, D-dimer, and length of hospital stay showed increasing trends, whereas lymphocyte count decreased. Univariate analysis showed that LogDLR was positively associated with AP severity (OR = 2,81, 95%CI: 1.70-4.66, P < 0.001). This association remained significant after adjustment for sex, age, body mass index, hypertension, and diabetes (OR = 3.33, 95%CI: 1.90-5.81, P < 0.001), and further adjustment for, triglycerides, total cholesterol, and low-density lipoprotein cholesterol (OR = 3.45, 95%CI: 1.95-6.07, P < 0.001). Compared with the lowest quartile, the risk of MSAP/SAP in patients classified within group Q4 was remained significantly elevated (model 1: Q4: OR = 4.21, 95% CI: 1.94-9.12, P < 0.001, model 2: Q4: OR = 5.34, 95% CI: 2.31-12.35, P < 0.001, model 3: Q4: OR = 5.57, 95% CI: 2.36-13.15, P < 0.001); all P < 0.001). The RCS analysis showed an overall association (P < 0.001) without statistically significant nonlinearity (P = 0.065). LogDLR showed the highest discriminatory ability for MSAP/SAP, with an AUC of 0.68 (95% CI: 0.61-0.75). Higher DLR was independently associated with greater odds of MSAP/SAP. Although its discriminatory performance was modest, DLR may complement established severity assessments as a readily available marker for early risk stratification in patients with AP.

PMID 43015610
Read full article →
PubMedFrontiers in medicine2026-11-12

Integrating multi-dimensional prosthodontic features into an interpretable XGBoost framework for cross-sectional diagnostic classification of peri-implant diseases.

Li Guojie G, Xu Naiwen N, Duan Zhijian Z, Zhou Guanjun G

The accurate prediction of peri-implant disease severity is crucial for timely intervention and successful long-term outcomes. This study aimed to develop and validate an interpretable machine learning model that evaluates whether multi-dimensional prosthodontic configurations alone, without relying on direct inflammatory indicators, can assist in classifying the cross-sectional severity of peri-implant diseases. A retrospective analysis was conducted on 300 implants from 285 patients. Data encompassed patient demographics, implant characteristics, and prosthodontic features, including Margin Fit (MF), Screw Access Space (SAS), prosthesis type, prosthesis material, and implant position. To prevent label leakage and tautological reasoning, direct diagnostic criteria (Probing Depth and Bleeding Index) were strictly excluded from the predictor matrix. The dataset was partitioned at the patient level into an internal training set (n = 200 patients; 210 implants) and an internal hold-out validation set (n = 85 patients; 90 implants). Four machine learning algorithms (Ordinal Logistic Regression, SVM, Random Forest, and XGBoost) were developed and validated. Model performance was evaluated using accuracy, F1-score, and AUC. Model interpretability was assessed using SHapley Additive exPlanations (SHAP), and clinical utility was determined via Decision Curve Analysis (DCA). A nomogram was also constructed. The XGBoost model achieved the highest discriminative performance on the internal validation set, with an overall accuracy of 78.9% and a macro-averaged AUC of 0.821 (95% CI: 0.760-0.882). SHAP analysis identified Margin Fit, Screw Access Space, and prosthesis material as the most influential features associated with disease stage classification. Decision Curve Analysis (DCA) demonstrated a positive clinical net benefit across decision threshold probabilities from 15% to 65%. The multivariable ordinal logistic regression model yielded a diagnostic AUC of 0.774, confirming the additional discriminative gain provided by non-linear ML ensembles. A non-linear machine learning framework incorporating prosthodontic features-free of label-leaking clinical indices-can objectively aid in classifying peri-implant disease stages in a cross-sectional setting. This tool should be framed as an automated diagnostic aid rather than a longitudinal prognostic system, pending multi-center external validation.

PMID 43016695
Read full article →
PubMedGlobal spine journal2026-11-11

Intrawound Vancomycin Powder in Posterior Lumbar Fusion: In Vitro Osteoblast Effects and Clinical Outcomes in a Historical-Control Cohort.

Truumees Heili H, Friedman Lindley I N LIN, Schmirler Joshua J, Sinclair Sarina S et al.

Study DesignRetrospective analysis.ObjectivesTo analyze the immediate post-operative effects on osteoblast activity, and long-term impact on bone healing, of intrawound vancomycin powder following posterior lumbar fusion (PLF).MethodsThis study had two phases: (1) an in vitro analysis of vancomycin effects on osteoblasts and (2) a retrospective chart review-spanning over a decade-analyzing outcomes of vancomycin use in PLF patients. Cellular metabolic and osteogenic activities were evaluated using well-established in vitro assays. The retrospective chart review included patients ages 18+ who underwent PLF (four levels or fewer) between January 2007-December 2015. Patients were divided into two groups: the pre-vancomycin group (PVG) and the vancomycin group (VG). Statistical analyses included descriptive and comparative analyses across groups.ResultsPhase One included 56 patients. Drain vancomycin concentrations peaked at POD 0, averaging 1253.67 ng/µL. Osteoblasts exposed to vancomycin concentrations of 1,250 ng/µL had significantly lower ALP activity compared to those exposed to 0, 245, 285, and 500 ng/µL (ps<0.05). Phase Two included 425 patients: 232 in the PVG and 193 in the VG. SSIs requiring debridement were observed in 3.02% of PVG patients compared to 2.07% of VG patients (p=0.761). There were no differences in pseudoarthrosis across cohorts (p=0.886), but lucency was more common in the VG (25.39%) than the PVG (11.64%; p<0.001).ConclusionsLocal drain concentrations of vancomycin decreased significantly across the postoperative period, suggesting its effects on osteoblasts are limited to the early inflammatory phase. In the long-term, intrawound vancomycin may not impact risk of SSI or pseudoarthrosis.

PMID 43012129
Read full article →
PubMedParasites & vectors2026-11-11

Mitogenomic insights into Sarcoptes scabiei in American black bears (Ursus americanus): COI utility for regional surveillance and mite genetic structure.

Francisco Raquel R, Grunert Ryan K A RKA, Rivera Reyes Jomari J, Broadhurst Jillian R JR et al.

Sarcoptic mange is a skin disease caused by the parasitic mite Sarcoptes scabiei that affects humans and over 150 species of domestic animals and wildlife worldwide. For the American black bear (Ursus americanus), sarcoptic mange is considered a significant emerging disease and case numbers have increased dramatically over the past four decades. While molecular techniques, such as DNA sequencing, are commonly used for diagnosis of clinical cases, they remain underutilized for studying cross-species transmission and regional mite variation. We captured complete mitochondrial genomes from S. scabiei mites (n = 17) collected from infested black bears in the Eastern United States (U.S.) using custom-designed oligonucleotide baits. These full mitogenomes were then used to refine primers targeting the cytochrome c oxidase subunit I (COI) gene. We then amplified and analyzed 285 COI sequences from S. scabiei collected across multiple North American wildlife hosts to assess their utility in inferring regional diversity and host-associated genetic structure. Full mitogenome comparisons with sequences from the U.S., Japan, and Australia revealed three major global S. scabiei clades, with two circulating among North American black bears. The COI haplotype networks showed regional clustering rather than host-specific patterns, suggesting that ecological or geographic factors influence transmission dynamics. Our findings confirm the presence of multiple S. scabiei lineages in American black bears and other U.S. wildlife and support the use of the COI gene for large-scale, cost-effective screening of genetic variation and shared haplotypes across host species. The integration of mitogenome and COI data offers a scalable model for investigating S. scabiei diversity in wildlife and domestic hosts.

PMID 43010067
Read full article →
PubMedThe lancet. Psychiatry2026-11-11

Comparative efficacy and tolerability of pharmacological interventions for the acute treatment of obsessive-compulsive disorder across the lifespan: a systematic review and network meta-analysis.

Cohen Sem S, Ostinelli Edoardo E, Takamiya Akihiro A, Storosum Bram B et al.

Pharmacological treatment is recommended for obsessive-compulsive disorder. Several options are available, yet little is known on comparative effects of individual medications. We aimed to elucidate the efficacy and tolerability of pharmacotherapy for people with obsessive-compulsive disorder, across the lifespan. We did a systematic review and network meta-analysis comparing short-term pharmacological interventions for obsessive-compulsive disorder. We searched multiple databases, including MEDLINE, Embase, PsycInfo, and the Cochrane Central Register of Controlled Trials, for literature on licensed or recommended pharmacological treatments for obsessive-compulsive disorder, without age restrictions, from database inception up to March 11, 2026. We included double-blind, randomised controlled trials with outcomes between 8 and 16 weeks. Two reviewers independently and in duplicate extracted outcomes, with a quality check done by a third reviewer. Primary outcomes were efficacy, defined as change from baseline score, and tolerability, defined as the proportion of participants discontinuing treatment due to adverse events. Separately for children and adolescents (aged 0-17 years) and adults (aged ≥18 years), we calculated standardised mean differences (SMDs) and odds ratios (ORs) with random-effects pairwise and network meta-analysis. The certainty of evidence was assessed using the Confidence in Network Meta-Analysis (CINeMA) framework. People with lived experience of obsessive-compulsive disorder were involved in the entire review process, including protocol development, writing, and interpretation of the findings. The study was preregistered in Open Science Framework (identifier 4V3GS). We included 52 randomised controlled trials with 7316 participants. Nine trials were included for children and adolescents (N=822; median age 12·5 years [IQR 11·6-13·2]; 352 [55%] male and 285 [45%] female among 637 participants with reported sex distribution). 43 trials were included for adults (N=6494; median age 36·4 years [35·0-37·9]; 3105 [49%] male and 3200 [51%] female among 6305 participants with reported sex distribution). Data on ethnicity were reported in 15 (29%) of 52 randomised controlled trials, using inconsistent definitions. In children and adolescents, clomipramine was more efficacious than placebo (SMD -1·19, 95% CI -1·73 to -0·64, CINeMA low), as were sertraline (-0·52, -0·80 to -0·02, low), fluoxetine (-0·43, -0·76 to -0·10, low), and fluvoxamine (-0·39, -0·71 to -0·07, low). Clomipramine was more efficacious than fluoxetine (SMD -0·75, 95% CI -1·39 to -0·11; very low), fluvoxamine (-0·79, -1·43 to -0·16; very low), paroxetine (-0·87, -1·51 to -0·22; very low), and sertraline (-0·87, -1·51 to -0·22; very low). Only sertraline was less tolerable than placebo (OR 4·51, 95% CI 1·36 to 14·96; low). In adults, clomipramine (SMD -0·71, 95% CI -0·88 to -0·54; high), fluvoxamine (-0·63, -0·83 to -0·43; high), paroxetine (-0·51, -0·73 to -0·29; moderate), sertraline (-0·49, -0·70 to -0·28; moderate), escitalopram (-0·43, -0·85 to -0·02; moderate), and fluoxetine (-0·37, -0·6 to -0·08; moderate) were more efficacious than placebo, and clomipramine was more efficacious than fluoxetine (-0·34, -0·65 to -0·04; low). Clomipramine (OR 4·65, 95% CI 3·27 to 6·60; moderate), fluvoxamine (2·73, 1·77 to 4·20; moderate), fluoxetine (2·52, 1·27 to 4·98; moderate), sertraline (2·23, 1·49 to 3·34; moderate), and paroxetine (1·99, 1·36 to 2·93; moderate) were less tolerable than placebo. Clomipramine was less tolerable than all active comparators (OR range 1·70 to 3·50; moderate) except fluoxetine (moderate) and venlafaxine (low). Clomipramine showed the largest estimated efficacy for obsessive-compulsive disorder but had a lower tolerability than SSRIs. The evidence of its superiority over individual SSRIs was more pronounced in children and adolescents. Our findings suggest that the trade-off between efficacy and tolerability should be discussed within an individualised, shared, decision-making framework. None.

PMID 43014332
Read full article →
PubMedNucleic acids research2026-11-10

gcPathogen 2.0: an expanded multi-omics database advancing global pathogen surveillance and One Health research.

Chen Qi Q, Guo Chongye C, Wang Ligui L, Fan Guomei G et al.

Launched in 2024, gcPathogen established a critical foundation for the genomic surveillance of human pathogens. Here, we present gcPathogen 2.0, a major multi-omics update designed to address key analytical bottlenecks, including the integration of genomic and transcriptional profiles, systematic tracking of cross-habitat distribution, and large-scale discovery of antimicrobial peptides (AMPs). This release expands coverage from 1134 to 1506 pathogenic species, spanning 557 bacteria, 508 fungi, 258 viruses, and 183 parasites, and increases total genomic records past 2.3 million. By incorporating 12 597 transcriptomes across 148 species, gcPathogen 2.0 bridges the gap between gene carriage and functional expression for risk assessment. Furthermore, the platform integrates 285 925 pathogen metagenome-assembled genomes (MAGs) spanning human, animal, and environmental niches. Mapped across 68 Environment Ontology (ENVO) habitat categories, these MAGs enable comprehensive tracking of cross-habitat distribution of pathogens, antibiotic resistance genes (ARGs), virulence factors (VFs), and mobile genetic elements (MGEs). Leveraging a nonredundant reference set curated from seven public databases, we identified over 77 million AMPs belonging to >55 000 families across 438 bacterial pathogens. Finally, pan-genome analyses of 440 bacterial species map intraspecies functional distributions across core, accessory, and unique gene repertoires. gcPathogen 2.0 is publicly accessible at https://nmdc.cn/gcpathogen/.

PMID 43006134
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Hoe-285